CN102038684A - Drug composition for relieving cough and reducing phlegm - Google Patents
Drug composition for relieving cough and reducing phlegm Download PDFInfo
- Publication number
- CN102038684A CN102038684A CN2009103083679A CN200910308367A CN102038684A CN 102038684 A CN102038684 A CN 102038684A CN 2009103083679 A CN2009103083679 A CN 2009103083679A CN 200910308367 A CN200910308367 A CN 200910308367A CN 102038684 A CN102038684 A CN 102038684A
- Authority
- CN
- China
- Prior art keywords
- butamirate
- guaifenesin
- dextromethorphan hydrobromide
- cough
- relieving cough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 206010011224 Cough Diseases 0.000 title claims abstract description 16
- 206010062717 Increased upper airway secretion Diseases 0.000 title abstract description 8
- 208000026435 phlegm Diseases 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 title description 5
- 229940079593 drug Drugs 0.000 title description 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960002146 guaifenesin Drugs 0.000 claims abstract description 21
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims abstract description 18
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 235000020357 syrup Nutrition 0.000 claims abstract description 5
- 239000006188 syrup Substances 0.000 claims abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 229960003860 butamirate citrate Drugs 0.000 claims description 12
- RBKASMJPSJDQKY-RBFSKHHSSA-N tirilazad Chemical compound O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 RBKASMJPSJDQKY-RBFSKHHSSA-N 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 206010036790 Productive cough Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 2
- 229960004902 butamirate Drugs 0.000 abstract description 15
- DDVUMDPCZWBYRA-UHFFFAOYSA-N butamirate Chemical compound CCN(CC)CCOCCOC(=O)C(CC)C1=CC=CC=C1 DDVUMDPCZWBYRA-UHFFFAOYSA-N 0.000 abstract description 15
- 238000002360 preparation method Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 238000002636 symptomatic treatment Methods 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 2
- -1 troches Substances 0.000 abstract 2
- 239000000890 drug combination Substances 0.000 abstract 1
- 229940100688 oral solution Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000000954 anitussive effect Effects 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000008213 purified water Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 229940124584 antitussives Drugs 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010062530 Increased bronchial secretion Diseases 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a drug combination for relieving cough and reducing phlegm, which is composed of active constituents and a pharmaceutic adjuvant, wherein the active constituents comprise butamirate critrate, dextromethorphan hydrobromide and guaifenesin. The composition can be prepared into various kinds of oral preparations such as granules, troches, capsules, oral solution, syrup and the like and can be used for carrying out symptomatic treatment on related diseases with symptoms of cough, abundance of phlegm and the like.
Description
Technical field
The present invention is a kind of pharmaceutical composition that is used for the relieving cough and reducing sputum, belongs to medical technical field.
Background technology
Butamirate is a central antitussive, and antitussive effect is stronger 5 times than codeine.Can promote the mucous secretion of bronchus.Be applicable to the cough that treatment upper respiratory tract infection causes.
Dextromethorphan hydrobromide is a central antitussive, to the selective inhibitory action of coughing centre, thereby plays antitussive effect.Antitussive action is rapid-action, and it is remarkable to suppress the cough program, does not have analgesic activity, and life-time service is not found toleration and addiction.
Guaifenesin is the http://www.a-hospital.com/%B6%F1%D0%C4.html expectorant http://www.a-hospital.com/%EC%EE%CC%B5%D2%A9.html that feels sick.Can stimulate gastric mucosa after oral, cause the bronchorrhea secretion increasing reflectingly.More weak sterilization antisepsis is still arranged in addition.Be mainly used in and eliminate the phlegm and thick productive cough that tracheitis, bronchitis, flu http://www.a-hospital.com/%B8%D0%C3%B0.html etc. the cause http://www.a-hospital.com/%BF%C8%CB%D4.html that coughs, also can share with control asthma with other antiasthmatics.
Summary of the invention
The present invention is a kind of pharmaceutical composition that is used for the relieving cough and reducing sputum, it is characterized in that, is to be that active component and pharmaceutic adjuvant combine with butamirate citrate, dextromethorphan hydrobromide, guaifenesin.Said composition can be made into oral formulations, comprises granule, tablet, capsule, oral liquid, syrup etc.Wherein the unit formulation input amount of butamirate citrate is 2-500mg, preferred 10-100mg.The unit formulation input amount of dextromethorphan hydrobromide is 3-150mg, preferred 7.5-60mg.
The unit formulation input amount of guaifenesin is 20-800mg, preferred 50-400mg.
Compositions of the present invention can be used for the symptomatic treatment with relevant diseases such as cough, excessive phlegm symptoms, and effect is remarkable, and two antitussive compositions can replenish potentiation mutually, and the ill effect that can resist the other side mutually simultaneously increases the safety of medication.
The specific embodiment
Embodiment 1: compound recipe butamirate granule:
Prescription:
Technology:
1. get dextromethorphan hydrobromide, butamirate citrate, guaifenesin is with equivalent incremental method mix homogeneously.
2. get above-mentioned hybrid medicine, anhydrous sodium phosphate, magnesium hydroxide, sodium carboxymethyl cellulose, xanthan gum, sucrose successively with equivalent incremental method mix homogeneously, add purified water system soft material, 18 mesh sieves are granulated, 50 ℃ of oven dry, 18 mesh sieve granulate.
3. add artificial cherry essence, artificial flavoring banana essence, mix homogeneously, packing, every bag of 2g.
Embodiment 2: compound recipe butamirate tablet
Prescription:
| Dextromethorphan hydrobromide | 5g |
| Butamirate citrate | 1.75g |
| Guaifenesin | 15.0g |
| Lactose | 80.0g |
| Microcrystalline Cellulose | 85.25g |
| Cross-linking sodium carboxymethyl cellulose | 10.0g |
| Colloidal silica | 2.0g |
| Magnesium stearate | 1.0g |
| Preparation altogether | 1000 |
Technology:
1. get dextromethorphan hydrobromide, butamirate citrate, guaifenesin is with equivalent incremental method mix homogeneously.
2. get above-mentioned hybrid medicine, lactose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose successively with equivalent incremental method mix homogeneously, add purified water system soft material, 18 mesh sieves are granulated, 50 ℃ of oven dry, 24 mesh sieve granulate.
3. add colloidal silica, magnesium stearate, mix homogeneously, tabletting, the heavy 200mg of sheet.
Embodiment 3: compound recipe butamirate capsule
Prescription:
| Dextromethorphan hydrobromide | 5g |
| Butamirate citrate | 1.75g |
| Guaifenesin | 15.0g |
| Lactose | 80.0g |
| Microcrystalline Cellulose | 85.25g |
| Cross-linking sodium carboxymethyl cellulose | 10.0g |
| Colloidal silica | 2.0g |
| Magnesium stearate | 1.0g |
| Preparation altogether | 1000 |
Technology:
1. get dextromethorphan hydrobromide, butamirate citrate, guaifenesin is with equivalent incremental method mix homogeneously.
2. get above-mentioned hybrid medicine, lactose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose successively with equivalent incremental method mix homogeneously, add purified water system soft material, 18 mesh sieves are granulated, 50 ℃ of oven dry, 24 mesh sieve granulate.
3. add colloidal silica, magnesium stearate, mix homogeneously, fill, the heavy 200mg of every capsules.
Embodiment 4: compound recipe butamirate oral liquid
Prescription:
| Dextromethorphan hydrobromide | 5g |
| Butamirate citrate | 1.75g |
| Guaifenesin | 15.0g |
| Sucrose | 400.0g |
| Sodium benzoate | 1.50g |
| Citric acid | 0.25g |
| Purified water | Be settled to 1000ml |
Technology:
1, takes by weighing recipe quantity sucrose and be added in the 600ml purified water, be heated to 100 ℃ and be stirred to dissolving fully.
2, dextromethorphan hydrobromide, butamirate citrate, guaifenesin, sodium benzoate, the citric acid of adding recipe quantity are stirred to dissolving fully.
3, add purified water to total amount.
4, filter
5, intermediate check
6, packing
Embodiment 5: compound recipe butamirate syrup
Prescription:
| Dextromethorphan hydrobromide | 5g |
| Butamirate citrate | 1.75g |
| Guaifenesin | 15.0g |
| Propylene glycol | 100ml |
| Methyl hydroxybenzoate | 0.25g |
| Propylparaben | 0.25g |
| Ethanol | 22.5ml |
| The liquid orange flavor | 2.5ml |
| Water | 250ml |
| Citric acid | 2.0g |
| Sodium citrate | 1.25g |
| Simple syrup adds to | 1000ml |
Technology:
(1). measure the purified water and the propylene glycol of recipe quantity, stir, add principal agent, be heated to 60 ℃ of stirrings and make dissolving fully.
(2). the citric acid, the sodium citrate that add recipe quantity are stirred to dissolving fully.
(3). get the ethanol of recipe quantity, add methyl hydroxybenzoate and propyl ester, stir and make dissolving, alcoholic solution is added in the medicinal liquid, stir.
(4). add the essence of recipe quantity, stir.
(5). this medicinal liquid is filtered with 0.8 microporous filter membrane, add simple syrup to total amount then and get final product.
(6). intermediate detects, and qualified back is divided in the syrup bottle of packing into.
Embodiment 6: pharmacological evaluation
1. mice ammonia draws the method for coughing: 40 of mices, be divided into 4 groups, and irritate stomach respectively and give compound recipe butamirate (45.5mg/kg), dextromethorphan hydrobromide (10.5mg/kg), guaifenesin (31.5mg/kg), equal-volume normal saline.Behind the administration 30min, mice is accepted the constant voltage ammonia spraying, cough number of times in the observed and recorded 3min.
2. the phenol red drainage method of mice: 80 of XII healthy male mices, be divided into 4 groups, irritate stomach respectively and give compound recipe butamirate (45.5mg/kg), dextromethorphan hydrobromide (10.5mg/kg), guaifenesin (31.5mg/kg), equal-volume normal saline.Administration 30min pneumoretroperitoneum is injected 5% phenol red solution 0.5mL, every 30min mice is died of asphyxiation again, cut the trachea section to the trachea crotch from thyroid cartilage, be soaked in the 30min that vibrates in the 1mL normal saline, add 5%NaHCO then, 1mL gets and is soaked in spectrophotometer wavelength 546nm place mensuration optical density, compare with phenol red standard curve, obtain its phenol red amount.
The result:
1, to the antitussive effect of mice
The right U.S. husky cough number of times that all can reduce mice of compound recipe butamirate and hydrobromic acid, the guaifenesin effect is not obvious, it is right U.S. husky that the antitussive effect of compound recipe group dosage group obviously is better than folk prescription, coughs good antitussive effect so the compound recipe butamirate draws the ammonia of mice.See Table 1
The antitussive effect of table 1 pair mice (
N=10)
| Group | Dosage (mg/kg) | The cough number of times | Suppression ratio (%) |
| Model group | --- | 59.6±3.9 | --- |
| The compound recipe butamirate | 45.5 | 12.1±2.4 | 79.7 |
| Dextromethorphan hydrobromide | 10.5 | 20.6±1.9 | 66.0 |
| Guaifenesin | 31.5 | 41.7±3.6 | 30.0 |
2, to the phlegm-dispelling functions of mice
Compound recipe butamirate and guaifenesin all can increase the phenol red excretion of mice trachea, and the effect of folk prescription dextromethorphan is not obvious, and the phlegm-dispelling functions of compound recipe group dosage group is significantly higher than the folk prescription guaifenesin.So the compound recipe butamirate has expectorant effect preferably to mice, sees Table 2
The phlegm-dispelling functions of table 2 pair mice (
N=20)
| Group | Dosage (mg/kg) | Phenol red output (μ g/ml) | Increase percentage rate (%) |
| Model group | 2.6±1.3 | ||
| The compound recipe butamirate | 45.5 | 11.4±3.0 | 338.5 |
| Dextromethorphan hydrobromide | 10.5 | 4.0±2.5 | 53.8 |
| Guaifenesin | 31.5 | 8.7±3.1 | 234.6 |
Claims (5)
1. being used for the pharmaceutical composition of relieving cough and reducing sputum, it is characterized in that, is to be that active component and pharmaceutic adjuvant combine with butamirate citrate, dextromethorphan hydrobromide, guaifenesin.
2. the described compositions of claim 1 is characterized in that, can be made into oral formulations, comprises granule, tablet, capsule, oral liquid, syrup etc.
3. the described compositions of claim 1 is characterized in that, the unit formulation input amount of butamirate citrate is 2-500mg, preferred 10-100mg.
4. the described compositions of claim 1 is characterized in that, the unit formulation input amount of dextromethorphan hydrobromide is 3-150mg, preferred 7.5-60mg.
5. the described compositions of claim 1 is characterized in that, the unit formulation input amount of guaifenesin is 20-800mg, preferred 50-400mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103083679A CN102038684A (en) | 2009-10-16 | 2009-10-16 | Drug composition for relieving cough and reducing phlegm |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103083679A CN102038684A (en) | 2009-10-16 | 2009-10-16 | Drug composition for relieving cough and reducing phlegm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102038684A true CN102038684A (en) | 2011-05-04 |
Family
ID=43905449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009103083679A Pending CN102038684A (en) | 2009-10-16 | 2009-10-16 | Drug composition for relieving cough and reducing phlegm |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102038684A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112972439A (en) * | 2019-12-16 | 2021-06-18 | 南京亿华药业有限公司 | Yumei effervescent tablet and preparation method thereof |
| CN113354547A (en) * | 2021-07-08 | 2021-09-07 | 江西善渊药业有限公司 | Crystallization process of citric acid butamifester |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS254358B1 (en) * | 1985-04-18 | 1988-01-15 | Frantisek Kubec | Antitusic-expectoration agent |
| CN1771955A (en) * | 2005-11-04 | 2006-05-17 | 浙江万联药业有限公司 | Soft capsule composition of compound cough-relieving and phlegm-eliminating medicine |
-
2009
- 2009-10-16 CN CN2009103083679A patent/CN102038684A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS254358B1 (en) * | 1985-04-18 | 1988-01-15 | Frantisek Kubec | Antitusic-expectoration agent |
| CN1771955A (en) * | 2005-11-04 | 2006-05-17 | 浙江万联药业有限公司 | Soft capsule composition of compound cough-relieving and phlegm-eliminating medicine |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112972439A (en) * | 2019-12-16 | 2021-06-18 | 南京亿华药业有限公司 | Yumei effervescent tablet and preparation method thereof |
| CN113354547A (en) * | 2021-07-08 | 2021-09-07 | 江西善渊药业有限公司 | Crystallization process of citric acid butamifester |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526058A (en) | Anti-inflammatory analgesic medicinal composition containing lornoxicam and esomeprazole | |
| CN102805746B (en) | A kind of act on respiratory system disease compound chemical medicine and preparation technology and application | |
| CN102038684A (en) | Drug composition for relieving cough and reducing phlegm | |
| CN101057861B (en) | Polycarbophil enteric coated medicinal composition | |
| CN101406629A (en) | Buccal tablets for treating painful swelling of gingiva and preparation method thereof | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN103599346B (en) | A kind of Chinese medicine composition for the treatment of cough | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN100356944C (en) | Medicine for relieving-cough and asthma | |
| EP3069723B1 (en) | Naringin and levocetirizine hydrochloride pharmaceutical composition and preparation thereof | |
| CN102397458A (en) | Pharmaceutical composition for treating senile pneumonia and preparation method thereof | |
| CN102552440B (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN1931279A (en) | Medicine for treating biliary tract infection and its prepn process | |
| CN103432596B (en) | Method for researching abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets | |
| CN102038681A (en) | Medicinal composition for relieving cough and reducing phlegm | |
| CN101579342A (en) | Desloratadine-contained patulin composition | |
| CN104188998A (en) | Naringin and fexofenadine hydrochloride drug composition and preparation thereof | |
| CN100391454C (en) | Preparation of hydrobromic acid dextro methaphen and beta cyclodeatrin compounding object | |
| CN1282479C (en) | Slowly-released traditional Chinese medicine adhering tablet for treating mouth mucous diseases and its prepn. method | |
| CN105343503B (en) | A kind of pharmaceutical composition that treating sphagitis and its application | |
| CN101862392B (en) | New pharmaceutical application of cordate houttuynia in thrombus prevention | |
| CN102038704A (en) | Pharmaceutical composition for treating cold in children and preparation method thereof | |
| CN103083524A (en) | Traditional Chinese medicine granules used for treating chicken aspergillosis, and preparation method thereof | |
| CN107773593A (en) | A kind of infantile heat-clearing and antitussive Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN1562314A (en) | Effervesce tablet of reducing fever and detoxicating and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110504 |